Shockwave Appoints Keith D. Dawkins M.D. as Chief Medical Officer
May 15 2019 - 7:00AM
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the
development and commercialization of Intravascular Lithotripsy
(IVL) to treat complex calcified cardiovascular disease, announced
today that the Company has appointed Keith D. Dawkins, M.D. as
Chief Medical Officer.
“Given the challenges associated with treating calcium
throughout the cardiovascular system, joining Shockwave and
contributing to the development of what will likely become the new
standard of care for calcium modification was an attractive
opportunity,” said Dr. Dawkins. “The Company has made significant
progress in the last year in both technology development and the
successful application of IVL to a variety of clinical settings; I
believe that the future potential of IVL has yet to be fully
realized.”
Prior to Shockwave, Dr. Dawkins served as Global Chief Medical
Officer and Executive Vice President to Boston Scientific
Corporation, as well as a member of that Company’s Executive
Committee from 2012 to 2017. This role followed Dr. Dawkins’ time
as Chief Medical Officer to the Boston Scientific Cardiology,
Rhythm and Vascular Group from 2010 to 2012. He joined Boston
Scientific in 2008 as Senior Vice President and Associate Chief
Medical Officer of the cardiovascular business. Earlier in his
career, Dr. Dawkins was a practicing interventional cardiologist
for more than 20 years in the U.K. He has earned a series of
clinical, research and academic distinctions, including a
Post-Doctoral Research Fellowship at Stanford University as a
Fulbright Scholar. Dr. Dawkins served as President of the British
Cardiovascular Intervention Society (BCIS) and held numerous
appointments on hospital, regional and national committees,
including the National Institute for Health and Clinical Excellence
(NICE). He has been an author on more than 750 academic
publications and presentations on a variety of cardiac topics.
“Having Keith join Shockwave brings a great depth of experience
to the organization,” said Doug Godshall, President and Chief
Executive Officer of Shockwave Medical. “His expertise from the
physician and industry perspective will offer significant value to
both our customers and teams across Shockwave as we continue to
expand access to our existing technology and to develop new
applications for IVL.”
Dr. Dawkins earned a First Class Honours degree in Pathology at
London University and Guy’s Hospital. He trained in cardiology at
Oxford and at the Royal Brompton & St. George’s Hospital in
London.
Dr. Dawkins will serve Shockwave on a half-time basis as he is
also currently serving as the Chief Medical Officer to 4TECH Cardio
Inc. and is a Senior Advisor to Conformal Medical, in addition to
serving on the Board of Directors for several companies including
Avicena, JenaValve and InnovHeart.
About Shockwave Medical, Inc. Shockwave Medical
is focused on developing and commercializing products intended to
transform the way calcified cardiovascular disease is treated by
establishing a new standard of care with Intravascular Lithotripsy
(IVL). The company’s differentiated and proprietary IVL approach to
calcium modification uses sonic pressure waves to safely and
effectively fracture problematic calcium throughout the
cardiovascular system in a wide and growing number of applications.
For more information, visit www.shockwavemedical.com.
Caution Regarding Forward-Looking
StatementsThis press release may contain forward-looking
statements regarding Shockwave’s current expectations. Words such
as “may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,”
“project,” “plan,” “intend” or similar expressions, or statements
regarding intent, belief, or current expectations are
forward-looking statements. These statements are not guarantees of
future performance and are subject to certain risks, uncertainties
and assumptions that are difficult to predict. Factors that could
cause actual results to differ include, but are not limited to,
those described more fully in the section captioned “Risk Factors”
in the final prospectus related to the public offering filed with
the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and
Shockwave undertakes no duty to update such information except as
required under applicable law.
Media Contact: Scott Shadiow
+1.317.432.9210sshadiow@shockwavemedical.com
Investor Contact:Debbie Kaster, Gilmartin
Groupinvestors@shockwavemedical.com
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Apr 2024 to May 2024
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From May 2023 to May 2024